持续与间歇循环利尿剂在急性心力衰竭 (DIUR-AHF) 的逐步协议:一种倾向匹配的分析
Gaetano Ruocco1,2, Andrea Salzano3,4,5, Sara Franceschi6
1Cardiovascular Research Institute Maastricht Maastrict University Maastricht Netherlands.
Journal of the American Heart Association
|March 10, 2026
概括
高剂量循环利尿剂在急性心力衰竭中增加不良事件并降低有效性. 这与低剂量治疗形成鲜明对比,建议谨慎使用高剂量策略,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环利尿剂是急性心力衰竭 (AHF) 拥堵的标准治疗方法.
- 最佳的剂量和使用策略尚不清楚.
研究的目的:
- 为了比较间歇性与连续性furosemide输液.
- 为了评估高剂量 (HD) 与低剂量循环利尿剂.
- 评估对AHF的拥堵,功能和临床结果的影响.
主要方法:
- 对DIUR-AHF研究数据的分析.
- 370名AHF患者接受了连续或间歇性IV循环利尿剂72-120小时.
- HD定义为>120毫克/天;在6个月的随访中评估结果.
主要成果:
- 与低剂量相比,HD循环利尿剂显示出类似的堵塞缓解,但降低了利尿效率.
- 患HD组的不良事件显著增加 (55%与20%相比).
- 多变量分析将HD治疗与出院后的较差结果联系起来 (HR 1.95).
结论:
- 高剂量的循环利尿剂在AHF增加不良事件的风险和减少利尿反应.
- 这些发现与先前对HD利尿剂的研究和慢性心力衰竭的预后一致.
- 需要进一步研究循环利尿反应与其他脱血疗法.
相关概念视频
Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Acute Kidney Injury V: Interprofessional Care
438
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
438
Heart Failure VI: Adjunct Therapies
494
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
Heart Failure V: Medical Management
453
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
323
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
323
Continuous Renal Replacement Therapy
1.5K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.5K


